JPWO2020034941A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020034941A5
JPWO2020034941A5 JP2021507628A JP2021507628A JPWO2020034941A5 JP WO2020034941 A5 JPWO2020034941 A5 JP WO2020034941A5 JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021507628 A JP2021507628 A JP 2021507628A JP WO2020034941 A5 JPWO2020034941 A5 JP WO2020034941A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
variable region
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533770A (ja
JP7576022B2 (ja
JP2021533770A5 (https=
Publication date
Priority claimed from CN201810920403.6A external-priority patent/CN110818793A/zh
Application filed filed Critical
Publication of JP2021533770A publication Critical patent/JP2021533770A/ja
Publication of JPWO2020034941A5 publication Critical patent/JPWO2020034941A5/ja
Publication of JP2021533770A5 publication Critical patent/JP2021533770A5/ja
Application granted granted Critical
Publication of JP7576022B2 publication Critical patent/JP7576022B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507628A 2018-08-14 2019-08-13 抗IL-1β抗体およびその医薬組成物およびそれらの使用 Active JP7576022B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810920403.6 2018-08-14
CN201810920403.6A CN110818793A (zh) 2018-08-14 2018-08-14 抗IL-1β的抗体、其药物组合物及其用途
PCT/CN2019/100343 WO2020034941A1 (zh) 2018-08-14 2019-08-13 抗IL-1β的抗体、其药物组合物及其用途

Publications (4)

Publication Number Publication Date
JP2021533770A JP2021533770A (ja) 2021-12-09
JPWO2020034941A5 true JPWO2020034941A5 (https=) 2022-08-09
JP2021533770A5 JP2021533770A5 (https=) 2022-08-09
JP7576022B2 JP7576022B2 (ja) 2024-10-30

Family

ID=69524699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507628A Active JP7576022B2 (ja) 2018-08-14 2019-08-13 抗IL-1β抗体およびその医薬組成物およびそれらの使用

Country Status (15)

Country Link
US (2) US12286473B2 (https=)
EP (1) EP3845560A4 (https=)
JP (1) JP7576022B2 (https=)
KR (1) KR20210046024A (https=)
CN (2) CN110818793A (https=)
AU (1) AU2019320927B2 (https=)
BR (1) BR112021002794A2 (https=)
CA (1) CA3108414A1 (https=)
EA (1) EA202190518A1 (https=)
IL (1) IL280596B2 (https=)
MX (2) MX2021001778A (https=)
MY (1) MY209465A (https=)
PH (1) PH12021550298A1 (https=)
SG (1) SG11202101435XA (https=)
WO (1) WO2020034941A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
BR112022022089A2 (pt) * 2020-05-22 2022-12-13 R Pharm Overseas Inc Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss
WO2021257539A1 (en) * 2020-06-16 2021-12-23 Academia Sinica ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
CN116063488B (zh) * 2022-10-21 2025-09-30 杭州靶向食品科技有限公司 一种单克隆抗体及其治疗痛风的用途
CN116688130A (zh) * 2023-06-08 2023-09-05 桂林医学院附属医院 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用
KR102844307B1 (ko) 2023-09-26 2025-08-07 사회복지법인 삼성생명공익재단 비흡연자의 조기 폐암 진단용 바이오마커 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2824167C (en) * 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
EP1590369B1 (en) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DK1899378T3 (da) * 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
EP2468301A1 (en) 2007-05-29 2012-06-27 Novartis AG New indications for anti-IL-1-beta therapy
IN2012DN02634A (https=) 2009-10-15 2015-09-04 Abbvie Inc
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン, インコーポレイテッド 抗IL−1β抗体およびその使用方法
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
JP5918275B2 (ja) 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
CA2888583C (en) 2012-11-05 2022-03-29 Delenex Therapeutics Ag Binding members to il-1 beta
CN105324396A (zh) * 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
CN103554264B (zh) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 针对IL-1β和IL-17A的双特异性抗体及其应用
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
CN107474139B (zh) * 2017-06-23 2021-04-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途

Similar Documents

Publication Publication Date Title
JP2021533770A5 (https=)
CN108290948B (zh) 抗-cd47抗体及使用方法
JP5818804B2 (ja) ヒトil−22raに対するヒト化抗体
EP1786918A2 (en) Novel tetravalent bispecific antibody
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
CN115785268B (zh) 抗cd47抗体及其用途
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
JP2025026839A (ja) Muc18に特異的な抗体
CA3183462A1 (en) 4-1bb-binding protein and use thereof
US20230295324A1 (en) Ox40-targeted antibody, and preparation method therefor and application thereof
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JPWO2020034941A5 (https=)
JP7036471B2 (ja) デスレセプター4及びデスレセプター5に結合する非常に強力な抗体
WO2023134767A1 (zh) 一种靶向IL-18Rβ的抗体及其应用
CA3089649A1 (en) Anti-tip-1 antibodies and uses thereof
CN121013865A (zh) 抗cd180结合分子及其用途
CA3221903A1 (en) Anti-upar antibodies and uses thereof
CN120554511B (zh) 一种抗钙粘蛋白-17的抗体及其抗体药物偶联物
JP2025504012A (ja) 抗btla抗体および癌治療におけるその使用
RU2024109579A (ru) Анти-LAG3 антитело, фармацевтическая композиция и применение
KR20250152067A (ko) 항-il2ra 항체 및 이의 용도
KR20250167608A (ko) 항-bdca2 항체
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
CN120322458A (zh) Cd38单克隆抗体及其应用